Abstract: The present invention is related to a method for risk detection, diagnosis, prognosis and monitoring of Alzheimer's disease (AD). The method comprises the steps of: (1) measuring the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in a sample from the subject, and (2) comparing the level of GAPDH in the sample with two or more AD reference levels of GAPDH.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
December 7, 2021
Assignee:
DR. POWER STEM BIOMEDICAL RESEARCH INC., LTD.
Abstract: The present invention relates, to a laminin receptor peptide for use in the treatment of amyotrophic lateral sclerosis (ALS), which is also known as Motor Neurone Disease (MND) and can include Frontotemporal Dementia (FTD). The invention also encompasses the laminin receptor peptide, nucleic acids encoding the laminin receptor peptide, vectors comprising the nucleic acids and compositions comprising the laminin receptor peptide.
Abstract: Provided is a method for inducing differentiation of neural crest cells into neurons of the autonomic nervous system, the method including the step of culturing neural crest cells in the presence of at least one of a BMP signaling pathway activator, an SHH signaling pathway inhibitor, and a Wnt signaling pathway inhibitor.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
November 30, 2021
Assignee:
National Institute of Advanced Industrial Science and Technology
Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
Type:
Grant
Filed:
April 20, 2018
Date of Patent:
November 30, 2021
Assignee:
AMGEN INC.
Inventors:
Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu
Abstract: The present invention relates to a method for regulating localization of CCNY protein to synapses, comprising palmitoylation of CCNY protein. Specifically, the present invention relates to a method for regulating targeting of CCNY protein to synapses by regulating addition of a palmitoyl group to cysteine at position 7 and/or 8 on the CCNY protein. Therefore, the palmitoylation of CCNY, a postsynaptic protein known to be implicated in synaptic plasticity and learning and memory, is a critical process for CCNY to be localized in postsynaptic spines, and thus it can be found that CCNY plays an important role in synaptic functions.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
November 2, 2021
Assignee:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Mikyoung Park, Yuri Choi, Jung-hwa Hong, Eunsil Cho
Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
Abstract: Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
October 19, 2021
Assignee:
Advantage Therapeutics, Inc.
Inventors:
Markus Mandler, Achim Schneeberger, Frank Mattner, Walter Schmidt
Abstract: The present disclosure provides compositions, kits, and methods of promoting neural growth and/or neural survival using IL-17c. The compositions, kits, and methods can be used to promote neural growth and/or neural survival in a variety of conditions where such growth and survival is beneficial.
Type:
Grant
Filed:
July 7, 2016
Date of Patent:
October 5, 2021
Assignees:
Fred Hutchinson Cancer Research Center, University of Washington
Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
September 28, 2021
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Bruce M. Spiegelman, Christiane D. Wrann
Abstract: This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
September 21, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Bruce D. Hammock, Christophe Morisseau, Jun Yang, Kenji Hashimoto
Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
Type:
Grant
Filed:
October 27, 2017
Date of Patent:
September 21, 2021
Assignee:
Washington University
Inventors:
David Holtzman, Hong Jiang, Fan Liao, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
September 7, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
Abstract: This disclosure relates to an amyloid beta peptide (A?)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.
Type:
Grant
Filed:
November 7, 2017
Date of Patent:
August 31, 2021
Assignee:
DegenRx B.V.
Inventors:
Samantha Kathleen Cobb, Michael Foley, Augustinus Petrus Henricus Scheefhals, Armand Wilbrandt Jannes Wichert Tepper
Abstract: Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.
Type:
Grant
Filed:
September 5, 2019
Date of Patent:
August 31, 2021
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.
Type:
Grant
Filed:
May 9, 2019
Date of Patent:
August 24, 2021
Assignee:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
LTD.
Abstract: The present invention shows that the isolated NFL-TBS40-63 peptide is highly specific for neural stem cells. It is therefore presented here for use in a method for detecting these cells in vitro or in vivo, for addressing chemical compounds or biological materials to said cells, or for treating neurodegenerative disorders or brain tumours.
Type:
Grant
Filed:
June 23, 2015
Date of Patent:
August 24, 2021
Assignees:
Universite D'Angers, Institut National de la Sante et de la Recherche Medicale (INSERM)
Abstract: An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A?1-42 or an N-terminal modified form thereof.
Abstract: The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in reducing damage caused by fine particulate matter on embryos and offspring. Accordingly, the present invention suggests that the Ganoderma immunomodulatory protein administrated to pregnant animals can prevent neurological damages and reduce risk of disorders in embryos and offspring.
Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.
Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
July 6, 2021
Assignee:
MedImmune Limited
Inventors:
Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe